Actively Recruiting
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Led by Air Force Military Medical University, China · Updated on 2024-05-06
208
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
CONDITIONS
Official Title
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-proven IgA nephropathy
- Proteinuria equal to or greater than 1.0 g/day while receiving maximum tolerated dose of RAS blockade
- Estimated glomerular filtration rate between 15 and 60 ml/min/1.73 m2
- Age 18 years or older
You will not qualify if you...
- Indication or contraindication for immunosuppressive therapy with corticosteroids
- Use of corticosteroids and other immunosuppressive drugs within the last 1 year
- Current unstable kidney function for other reasons
- Under 18 years old
- Patients with secondary IgA nephropathy
- Patients unlikely to comply with the study protocol according to the treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
AFMMU
Xi'an, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here